
TSE:CGY
This summary was created by AI, based on 1 opinions in the last 12 months.
Calian Group Ltd (CGY-T) has received positive feedback from experts, highlighting its strong company fundamentals and recent performance. The company has displayed robust momentum, achieving a 52-week high, which is encouraging for current and potential investors. There seems to be a consensus among analysts that Calian is solidly managed, with a well-structured operational strategy contributing to its success. This positive trajectory suggests that the company may continue to perform well in the near future, making it a strong candidate for both holding and considering for investment. Overall, the current outlook appears optimistic, with good prospects for sustained growth.
He used to own it a long time ago. It stalled out and he sold. It is finally getting traction again. They are trying to diversify the business. If they lose a big contract it could really impact the results. The dividend is safe. He would like to buy it much more cheaply but he would not buy at these levels.
It does 145 pharmacies by Loblaw’s (L-T) and medical services for the Canadian Defence Department, as well as a satellite business out of Saskatoon. One of the most consistently profitable small-cap companies for the last 5 years. 4% dividend yield. (Analysts’ price target is $31.00.)